New blood test being researched in the UK could detect cancer earlier

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

By Tanae Howard

INDIANAPOLIS - New technology being developed by researchers at the University of Bradford in the United Kingdom could be the future of early cancer diagnosis.

It’s called the lymphocyte genome sensitivity test. Researchers tested a couple hundred patients with cancer and those who were healthy. They looked at white blood cells under a UVA light. They found those with cancer had more damaged DNA than those who were healthy.

We spoke to a local oncologist who says this could be a medical breakthrough for early detection but there’s still more work to be done.

"Those with higher probability you can reach cancer diagnosis early and start treatment early and hopefully get better outcomes. And those with low probability of cancer you can avoid a lot of anxiety a lot of unnecessary test and can get some peace of mind to the patients and parents," said St. Vincent Child Oncologist, Dr. Bassem Razzouk.

The initial study involved patients with melanoma, lung cancer and colon cancer. Now the test will be performed on a wider range of subjects and different types of cancers.

Dr. Razzouk says the testing would also have to be validated. He projects it’s at least more than two years away from being on the market.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.